Search clinical trials for: recurrent NPC

Total 12160 results

Sun Yat-sen University

Recruiting

A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Recurrent or Metastatic Nasopharyngeal Carcinoma

China
Eye & ENT Hospital of Fudan University
Changhai Hospital; Shanghai Zhongshan Hospital; Fujian Medical University Union... and other collaborators

Not yet recruiting

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

Recurrent Nasopharyngeal Carcinoma

China
Eye & ENT Hospital of Fudan University
Changhai Hospital; Shanghai Zhongshan Hospital; Fujian Medical University Union... and other collaborators

Not yet recruiting

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

Recurrent Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Not yet recruiting

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

Nasopharyngeal Carcinoma | Recurrent and Metastatic Nasopharyngeal Carcinoma | Multi-omics Technique | Efficacy of Chemoradiotherapy and Immunotherapy

China
Sun Yat-sen University
JIANGSU JIBEIER PHARMACEUTICAL CO.,LTD

Not yet recruiting

A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC

Nasopharyngeal Carcinoma | Chemotherapy | Myelosuppression | Leucogen

China
Shanghai Henlius Biotech

Recruiting

Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC

Nasopharyngeal Carcinoma by AJCC V8 Stage

China
Eye & ENT Hospital of Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC

Recurrent Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure

PD-1 Inhibitor | G-CSF

China
Hoffmann-La Roche
PPD

Recruiting

A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis (Operetta 2)

Relapsing-Remitting Multiple Sclerosis

United States, Belgium, Canada, Spain, India, Italy, Mexico, Portugal, Argentina, Austria, Brazil, United Kingdom, Germany, Netherlands, Serbia, Australia, Bulgaria, France, Greece, Hungary, Poland, Ukraine, Estonia, Denmark, Croatia, Latvia and more
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fudan University

Recruiting

Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma (RETICULA-NPC)

Chemotherapy Effect | Immunotherapy | Recurrent Nasopharyngeal Carcinoma | Unresectable Nasopharyngeal Carcinoma | Stereotactic Body Radiation Therapy (SBRT)

China
National University Hospital, Singapore

Recruiting

A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma

Singapore
Sun Yat-sen University

Not yet recruiting

A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation

Nasopharyngeal Carcinoma
Sun Yat-sen University
Wuhan University; Tongji Hospital; Hunan Province Tumor Hospital; Second Affiliated... and other collaborators

Recruiting

Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma (IMRT)

Nasopharyngeal Carcinoma

China
National University Hospital, Singapore
Merck Sharp & Dohme LLC

Not yet recruiting

Bevacizumab and Pembrolizumab Combination in EBER-ISH Positive NPC (2018/00947)

Metastatic Nasopharyngeal Cancer | Locally Recurrent Cancer

Singapore
Shanghai Proton and Heavy Ion Center

Not yet recruiting

Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy

Recurrent Nasopharyngeal Carcinoma
The University of Hong Kong
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt...

Completed

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Nasopharyngeal Carcinoma | Metastatic Cancer | Recurrent Carcinoma | Non-keratinizing Carinoma

Hong Kong
Chinese University of Hong Kong

Active, not recruiting

NPC - AXEL Study : Axitinib-Avelumab

Recurrent or Metastatic NPC

Hong Kong
Shanghai Jiao Tong University School of Medicine

Completed

Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial

Head and Neck Squamous Cell Carcinoma | Oral Squamous Cell Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Recurrent or Metastatic NPC

China, Taiwan, Singapore
Novartis Pharmaceuticals

Completed

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

United States, China, Taiwan, Singapore, Hong Kong, Thailand, France
Chinese University of Hong Kong

Completed

Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy

Nasopharyngeal Cancer | Epstein-Barr Virus Infections

Hong Kong
The University of Hong Kong

Withdrawn

Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

Nasopharyngeal Carcinoma
Sun Yat-sen University
First People's Hospital of Foshan; Affiliated Cancer Hospital & Institute of... and other collaborators

Unknown

Endostar for Locally Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Fujian Cancer Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Unknown

EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Unknown

Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients

Nasopharyngeal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University

Completed

Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma

China
Celgene

Completed

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

Canada, United States, Taiwan, France, Spain, Greece, Italy, Singapore, Tunisia
Fujian Cancer Hospital
Zhejiang Cancer Hospital; Sun Yat-sen University; Jiangxi Provincial Cancer Hospital and other collaborators

Unknown

Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
Hong Kong Nasopharyngeal Cancer Study Group Limited
Sanofi; The University of Hong Kong; Merck Sharp & Dohme LLC; Roche Pharma AG

Completed

Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

China
Zhejiang Cancer Hospital

Unknown

Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Unknown

A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.

Recurrent Nasopharyngeal Carcinoma

China
Chinese University of Hong Kong

Completed

Nasopharyngeal Carcinoma (NPC) Axitinib

Recurrent or Metastatic NPC

Hong Kong
Chinese University of Hong Kong

Completed

MK-2206 in Recurrent Nasopharyngeal Carcinoma (MC1079)

Recurrent Nasopharyngeal Carcinoma

Hong Kong
Zhejiang Cancer Hospital

Unknown

A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Unknown

EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients

Nasopharyngeal Carcinoma

China
University Health Network, Toronto

Completed

Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer (NPC-CTL)

Nasopharyngeal Cancer

Canada
Fujian Cancer Hospital

Completed

Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma

Nasopharyngeal Cancer Recurrent

China
National Cancer Centre, Singapore

Unknown

Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer

Head and Neck Cancer

Singapore
Sun Yat-sen University

Completed

Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Nasopharyngeal Neoplasms

China
Nobelpharma

Completed

Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme

Malignant Glioma

Japan
Children's Cancer and Leukaemia Group

Unknown

Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma

Lymphoma
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC (NPC)

Head and Neck Cancer

United States
Sun Yat-sen University
Eli Lilly and Company

Completed

Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy

Nasopharyngeal Neoplasms

China
National Cancer Centre, Singapore

Unknown

Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer

Head and Neck Cancer

Singapore
National Taiwan University Hospital

Unknown

Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients

Nasopharyngeal Carcinoma | Recurrent

Taiwan
Peking Union Medical College Hospital

Not yet recruiting

A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag

Aplastic Anemia

China
Peking University Cancer Hospital & Institute

Recruiting

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

China

Search clinical trials for: recurrent NPC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations